Back to results
US 2018/0000904 A1Published application
Nasal powder formulation for treatment of hypoglycemia
AssigneeEli Lilly and Company
InventorsSankaram Mantripragada, Claude A. Piche, Jo Jan Filip Van Betsbrugge
Life of this patent
Estimating the term…
Abstract
The present invention provides a powder formulation containing glucagon or a glucagon analog for nasal administration, useful in the treatment of hypoglycemia, and in particular the treatment of severe hypoglycemia. The present invention also provides a method of making this powder formulation, and to devices and methods for using the powder formulation.
Claims19
1-21. (canceled)
A powder composition comprising glucagon (SEQ ID NO:
- 1), β-cyclodextrin, and dodecylphosphocholine, wherein the glucagon is present in an amount of about 5 to about 15 percent by weight, the β-cyclodextrin is present in an amount of about 44 to about 90 percent by weight, and the dodecylphosphocholine is present in an amount of about 5 to about 51 percent by weight and wherein the weight percentage is measured on an anhydrous, acetate-free basis.
Dependencies are inferred from the claim text.